(RTTNews) - Johnson & Johnson (JNJ) is close to acquiring eye disease drug developer Ollin Biosciences in a deal valued at up to $3.4 billion, according to a Financial Times report citing people familiar with the matter.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
